PharmaCyte Biotech exchanges warrants for 4,982,272 Q/C Technologies shares
PMCB•PharmaCyte Biotech agreed to exchange 851,304 Series G Long-Term Warrants for 4,982,272 Q/C Technologies common shares, with no additional consideration, and Q/C extended the maturity of its Series H Convertible Preferred Stock to September 2, 2027.




